In the article, the authors discuss issues over the use of alternative payment models in the U.S. health care sector. They reject the claim that the models are the main reason behind the growth slowdown in health care spending. They recommend the integration of randomized clinical trials (RCT) in the evaluation of the models to achieve better evidence for policy makers.